Coronary CTA for earlier detection of cardiac risk

Cardiovascular prevention often fails when it waits for symptoms, a high calcium score, or an abnormal stress test. The conversation between Dr. Nikki Burn and cardiovascular radiologist Kim Brockenbrough argues for a different standard: the right imaging test can show atherosclerosis before the damage becomes obvious. Coronary CTA, or coronary CT angiography with contrast, can reveal soft plaque that has not yet calcified and can be missed in active, lean, or apparently low risk people. That changes the risk discussion because clinicians are no longer treating lab values alone. They are treating real disease that can already be seen inside the artery wall.

Why a zero calcium score is not enough

Coronary calcium scoring is still useful because it is accessible, inexpensive, and gives a first signal of risk. The problem is that it does not show the whole picture. In the episode, the clinicians describe seeing many patients with a calcium score of zero who still have non calcified plaque. That matters because soft plaque is the phase most likely to rupture and trigger a heart attack, stroke, or broader vascular damage. A reassuring result can therefore create a false sense of safety.

The clearest example in the discussion was a 48 year old runner doing large amounts of weekly cardio who still had an 80% stenosis in the left anterior descending artery caused by soft plaque despite a zero calcium score. Another patient had a calcium score of one with a 90% obstruction. Both cases challenge the assumption that looking fit or training hard automatically means clean arteries. Biology does not always announce itself early, and clinical history alone can miss meaningful disease.

What coronary CTA adds compared with other tests

The major advantage of coronary CTA is that it shows both plaque burden and the degree of narrowing in the vessel. That helps separate very early disease that may respond to intensive lifestyle changes from situations where a more aggressive medical strategy is justified. A stress test usually turns positive only when narrowing approaches 70%. For a longevity oriented strategy, that threshold arrives late.

CTA also gives clinicians a more practical frame than an abstract conversation about cholesterol. Biomarkers still matter, but imaging shows what is happening inside the artery at the moment of the scan. That is why the episode repeatedly warns against confusing a single reassuring number with the absence of disease.

Who should think about it earlier

• Men in their forties and women in their fifties if risk factors are already present.
• People with high cholesterol, diabetes, insulin resistance, or a strong family history.
• Younger patients or women who may be falsely reassured by a negative calcium score.
• Cases where symptoms or concern persist despite a normal stress test.

The logic is straightforward: if disease can be seen years before the event, it makes sense to look for it earlier.

How to use the result to treat sooner

The value of finding soft plaque is not to frighten patients. It is to intervene while time still matters. The episode describes a practical framework. If plaque burden is small, clinicians can strengthen nutrition, exercise, weight control, and treatment adherence while monitoring change. If narrowing is severe or plaque burden is high, delaying action makes less sense.

This is where lipid lowering therapy enters the picture. The conversation covers statins and PCSK9 inhibitors as tools that can reduce soft plaque while increasing stable calcification, a shift the radiologist describes as moving plaque toward a less dangerous form. Treatment intensity should match what the scan shows. Managing theoretical risk is different from managing visible disease in the left anterior descending artery or the left main.

Follow up matters as well. In more significant disease, repeating imaging after one to two years can be reasonable. In milder cases, a three to five year interval may be enough. The point is to use imaging to verify whether the strategy is actually working rather than assuming it is.

Risks, limits, and common mistakes

Coronary CTA is not a test to use casually. It costs more, requires contrast, and exposes the patient to radiation. In people with kidney issues or concern for contrast reaction, the decision has to be individualized. Even so, the episode stresses that the risk is usually low when the test is well selected.

It is also worth remembering that not everything should be automated. The discussion is skeptical of some artificial intelligence plaque quantification tools when image quality is imperfect or when complex anatomy is reduced to a single number. Expert interpretation still matters, especially when the finding may change a major treatment decision.

Another common mistake is assuming that an asymptomatic patient does not need more information. That is a late stage model of medicine, designed to react after damage is advanced. If the goal is to preserve function, cognition, and independence for decades, finding coronary disease before the heart attack does change the plan.

The practical longevity takeaway

The main lesson from this episode is that cardiovascular prevention improves when we stop waiting for severe obstruction or chest pain. Coronary CTA does not replace every other tool, but it adds a critical layer of reality. If it shows clean arteries, that supports informed reassurance. If it shows soft plaque, it creates a chance to act while there is still room to change the trajectory. For a serious longevity strategy, seeing earlier so you can treat earlier is too clinically useful to ignore.